OTCMKTS:OTLC Oncotelic Therapeutics Q4 2025 Earnings Report $0.04 +0.00 (+3.97%) As of 06/26/2026 01:07 PM Eastern ProfileEarnings History Oncotelic Therapeutics EPS ResultsActual EPS$0.59Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AOncotelic Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOncotelic Therapeutics Announcement DetailsQuarterQ4 2025Date4/15/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Oncotelic Therapeutics Earnings HeadlinesOncotelic Launches AI-Powered GMP Manufacturing Services Platform at BIO International Convention 2026June 18, 2026 | globenewswire.comOncotelic Advances AI-Powered GMP Manufacturing Services Platform for Revenue-Generating AI and Robotics Manufacturing ServicesJune 17, 2026 | globenewswire.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.June 27 at 1:00 AM | Profits Run (Ad)Oncotelic Showcases PDAOAI™ Capability in Advancing Drug Development. Featured in Qdrant Vector Space Day 2026 KeynoteJune 8, 2026 | markets.businessinsider.comNetworkNewsAudio Announces Audio Press Release (APR) Discussing the Exploration of Nanoparticle, Targeted Drug-Delivery TechnologiesJune 5, 2026 | globenewswire.comOncotelic Therapeutics Inc. (OTCQB: OTLC) Eyeing Nanotech-Driven Delivery Systems, Pharmacokinetic Optimization to Advance Existing Oncology TherapiesJune 4, 2026 | globenewswire.comSee More Oncotelic Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Oncotelic Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oncotelic Therapeutics and other key companies, straight to your email. Email Address About Oncotelic TherapeuticsOncotelic Therapeutics (OTCMKTS:OTLC) is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity. Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs. The company has conducted early‐phase clinical studies in solid tumors and is exploring combination strategies with immune checkpoint inhibitors. Oncotelic’s research and development efforts are focused on expanding the potential of its oncolytic platform across multiple cancer indications and optimizing its diagnostic capabilities to support personalized treatment strategies. Headquartered in Gaithersburg, Maryland, Oncotelic operates with a lean scientific and management team. Leadership is spearheaded by President and Chief Executive Officer Bryan M. Saltjian, Ph.D., who brings extensive experience in viral immunotherapy and biotechnology commercialization. Under his guidance, Oncotelic aims to advance its pipeline through clinical milestones and strategic partnerships that can bring its oncolytic and diagnostic innovations to the broader oncology community.View Oncotelic Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings AloneFabrinet Is Becoming a Quiet Winner in the AI Optics BuildoutMicron’s HBM Surge Could Redefine the AI Growth StoryCarnival's Second Quarter: Is the Stock Still Complicated?Xcel Energy Stock Offers Stability as Electricity Demand BuildsThis Single Factor Is Holding Back Carvana’s Disruptive EdgePaychex Stock Looks Beaten Down, But Not Broken Upcoming Earnings NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)ASML (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
